Last week, we host­ed the most en­gag­ing event I’ve been a part of here at End­points News.

If you were there, you got to see a show­down of ideas be­tween some of the most im­por­tant voic­es in bio­phar­ma: We de­bat­ed the rise of Chi­na, the US re­sponse and how it will shape the glob­al fu­ture of biotech for pa­tients, com­pa­nies, gov­ern­ments, founders and in­vestors. It got in­tense at times, but it was al­so a ton of fun.

If you missed it (or if you want to re­live it), we’re mak­ing the au­dio and video record­ings avail­able here:

Has Chi­na changed how we build com­pa­nies? Roivant CEO Matt Gline + Strand Ther­a­peu­tics CEO/Founder Ja­cob Be­craft

In­vestor math ver­sus in­dus­tri­al pri­or­i­ties, with RA Cap­i­tal Man­ag­ing Part­ner/Founder Pe­ter Kolchin­sky, MIT Pro­fes­sor Fiona Mur­ray and Gink­go Bioworks CEO Ja­son Kel­ly